# Brazilian pharmaceutical industry investment and growth

> Live situation record from CLSTR: https://clstr.news/situations/brazilian-pharmaceutical-industry-investment-and-growth
> Updated: 2026-09-08T09:30:00.000Z. Sources: 4. Developments: 2.

The Brazilian pharmaceutical and wellness sectors are seeing significant investment and growth. In August 2026, Arese Pharma secured R$ 20 million in BNDES financing to enhance its manufacturing unit in Valinhos, São Paulo. This funding is directed toward research, development, and innovation to produce antidepressants and anti-inflammatories not currently available in Brazil, as well as creating new administration methods for pediatric and geriatric patients.

By September 2026, the market showed broader expansion, with the self-care and wellness segment reaching R$ 27.7 billion. During this period, the Italian company Chiesi announced a R$ 124 million investment to expand its Santana de Parnaíba facility. This expansion aims to increase production capacity for asthma and COPD inhalers by nearly 67% while utilizing new propellants to reduce carbon footprints.

## Timeline

### 2026-09-08: Brazil pharmaceutical market grows as Chiesi invests R$ 124 million

Brazil's wellness market has reached R$ 27.7 billion, while Italian firm Chiesi is investing R$ 124 million to expand its Brazilian factory and produce low-carbon asthma inhalers.

2 sources. https://clstr.news/cluster/brazil-pharmaceutical-market-grows-as-chiesi-invests-r-124-million

### 2026-08-24: Arese Pharma receives R$ 20 million in BNDES financing

Arese Pharma secured R$ 20 million from BNDES to develop new antidepressants and anti-inflammatories in Brazil, aiming to introduce active ingredients not currently available in the domestic market.

4 sources. https://clstr.news/cluster/arese-pharma-receives-r-20-million-in-bndes-financing

---
Cite as: Brazilian pharmaceutical industry investment and growth. CLSTR, https://clstr.news/situations/brazilian-pharmaceutical-industry-investment-and-growth